This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyPreferredfrequencyof GnRHagonistsThis agentshould beinitiated withneratinib for thefirst 8 weeksDuration of timepatients willtakeabemaciclib inearly stagediseaseThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This drugclass are thebackbone ofHR+ diseasePreferredregimen forHR+ diseasefor frail/elderlypatientsUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis agent canbe added toLN+ HER2+disease givenwithtrastuzumab1%This treatmentmodality isalwayscombined withlumpectomysurgeryThis agent cancauseendometrialcancer, but hasbone densityprotective effectThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score The onlysteroidalaromataseinhibitor in itsdrug classThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerBased onOncotype DX,a score of 35will receivethis treatmentThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyPreferredfrequencyof GnRHagonistsThis agentshould beinitiated withneratinib for thefirst 8 weeksDuration of timepatients willtakeabemaciclib inearly stagediseaseThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This drugclass are thebackbone ofHR+ diseasePreferredregimen forHR+ diseasefor frail/elderlypatientsUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis agent canbe added toLN+ HER2+disease givenwithtrastuzumab1%This treatmentmodality isalwayscombined withlumpectomysurgeryThis agent cancauseendometrialcancer, but hasbone densityprotective effectThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score The onlysteroidalaromataseinhibitor in itsdrug classThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerBased onOncotype DX,a score of 35will receivethis treatmentThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerI can give thisagent in highrisk BRCA1/2 mutationfor 1 year

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  2. Patients with HER2+ disease continue targeted therapy for this duration
  3. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  4. Preferred frequency of GnRH agonists
  5. This agent should be initiated with neratinib for the first 8 weeks
  6. Duration of time patients will take abemaciclib in early stage disease
  7. This subtype of breast cancer has the lowest relative 5-year survival rate
  8. This drug class are the backbone of HR+ disease
  9. Preferred regimen for HR+ disease for frail/elderly patients
  10. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  11. This agent can be added to LN+ HER2+ disease given with trastuzumab
  12. 1%
  13. This treatment modality is always combined with lumpectomy surgery
  14. This agent can cause endometrial cancer, but has bone density protective effect
  15. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  16. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  17. The only steroidal aromatase inhibitor in its drug class
  18. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  19. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  20. This should be monitored routinely every 3-4 months while receiving trastuzumab
  21. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  22. Based on Oncotype DX, a score of 35 will receive this treatment
  23. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  24. I can give this agent in high risk BRCA 1/2 mutation for 1 year